Atlas market file · Equity · United States
Innoviva, Inc.INVA
- Last close
- 21.11
- Change
- +2.93%
- 96-bar range
- 20.49 – 24.45
- As of
- 6 Aug 2026
Innoviva, Inc. is a pharmaceutical preparations issuer listed as INVA on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
INVA
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+11.93% over the window).
Source rail: Yahoo Finance chart API (INVA). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for INVA. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
INVA public profile
Pharmaceutical preparations issuer. Innoviva, Inc. is connected to current market context, cited company sources and its retained research file.
Innoviva, Inc. trades as INVA on NASDAQ. Innoviva, Inc. (INVA) has a latest verified close of 21.11, up 2.93%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files INVA under USA Stocks for browsing.
What changed for Innoviva, Inc. today
Innoviva, Inc. (INVA) reported $98 million in revenue and $38.2 million in operating income for the quarter ended March 31, 2026, buoyed by its portfolio of critical care and infectious disease products, including GIAPREZA®, XERAVA®, and XACDURO®. Notably, three key customers accounted for 77% of sales, highlighting a precarious revenue concentration that could unsettle even the most seasoned investor.
The company’s cash reserves stood at $603.1 million, underscoring its financial flexibility despite spending just $5.2 million on R&D and $492,000 on capex. Meanwhile, the abrupt resignation of two board members to focus on Syndeio BioSciences-a spinoff mentioned in a May 18 8-K filing-raises questions about governance stability amid a year-over-year 29% growth in U.S. net product sales.
INVA’s 10-Q reveals diluted EPS of $2.22 on 84.8 million shares outstanding, with operating cash flow of $35.3 million. However, the company’s inventory increased by $1.3 million, and its reliance on a narrow customer base remains a red flag. Investors await the second-half 2026 launch of an FDA-approved product, which could diversify revenue streams or exacerbate existing pressures.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
INVA technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on INVA
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep INVA research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
INVA FAQ
What is Innoviva, Inc. (INVA)?Innoviva, Inc. (INVA) has a latest verified close of 21.11, up 2.93%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
Innoviva, Inc. (INVA) has a latest verified close of 21.11, up 2.93%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for INVA?Innoviva, Inc. (INVA) has a latest verified close of 21.11, up 2.93%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and...
Innoviva, Inc. (INVA) has a latest verified close of 21.11, up 2.93%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files INVA under USA Stocks for browsing.
How often is the INVA page updated?The INVA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The INVA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for INVA?The INVA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:INVA. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The INVA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:INVA. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on INVA?Yes. The workstation can open INVA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open INVA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this INVA page investment advice?No. The INVA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The INVA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →